Patents Examined by Fozia M Hamud
  • Patent number: 11187704
    Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: November 30, 2021
    Assignee: CITY OF HOPE
    Inventor: Peter P. Lee
  • Patent number: 11173191
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: November 16, 2021
    Assignee: Altor Bioscience, LLC.
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Patent number: 11168138
    Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant, a cytokine receptor or cytokine ligand, and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 9, 2021
    Assignee: Altor Bioscience, LLC
    Inventors: Qiongzhen Li, Xiaoyun Zhu, Hing C. Wong
  • Patent number: 11167004
    Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 9, 2021
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Allen Radin, Neil Graham, Bolanle Akinlade, Gianluca Pirozzi, Xing Sun, Thomas Hultsch, Brad S. Shumel, Ashish Bansal
  • Patent number: 11156612
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Patent number: 11155624
    Abstract: The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 26, 2021
    Assignees: ANAPTYSBIO, INC., Tesaro, Inc.
    Inventors: David J. King, Marilyn Kehry, Baochuan Huang
  • Patent number: 11136387
    Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 5, 2021
    Inventors: Yizhen Yang, Shiyong Gong, Lijuan Hao, Jian Wu, Xinxiu Yang, Qin Zhong, Shaoping Hu, Stewart Leung, Qing Duan, Lile Liu
  • Patent number: 11130822
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: September 28, 2021
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • Patent number: 11117968
    Abstract: Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 14, 2021
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Kimberly Ann Tipton, James William West, Shrikant Deshpande, John J. Englehardt
  • Patent number: 11111306
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 7, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • Patent number: 11104745
    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-?. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-?. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-? antigen binding proteins, and pharmaceutical formulations thereof.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 31, 2021
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Gunasekaran Kannan, Kenneth W. Walker, Michelle Hortter, Edward J. Belouski
  • Patent number: 11084863
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 10, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • Patent number: 11059876
    Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: July 13, 2021
    Assignee: PFIZER INC.
    Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
  • Patent number: 11053309
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of active eosinophilic esophagitis. In certain embodiments, the present invention provides methods of increasing esophageal distensibility. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4/interleukin-13 (IL-4/IL-13) pathway inhibitor such as an anti-IL-4R antibody.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: July 6, 2021
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Allen Radin, Jennifer D. Hamilton, Leda Mannent
  • Patent number: 10973882
    Abstract: The described invention provides a method of treating a lung injury at risk of progressing to a fibrotic lung disease in a subject in need thereof comprising administering to the subject a composition comprising a therapeutic amount of IL-6 polypeptide, hyaluronan (HA), mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof, wherein the therapeutic amount is effective to increase renewal of alveolar epithelial cell 2 (AEC2) stem cells, to repair the injury, to reduce lung fibrosis, or a combination thereof.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 13, 2021
    Assignee: Cedars-Sinai Medical Center
    Inventors: Carol Jiurong Liang, Dianhua Jiang, Paul W. Noble
  • Patent number: 10512671
    Abstract: Methods are provided for treating ocular surface inflammation and/or uveitis in a subject. The methods can include selecting a subject with uveitis and/or ocular surface disease. The methods can then include administering to the subject a therapeutically effective amount of an interleukin 24 (IL-24) polypeptide or nucleic acid encoding the IL-24 polypeptide. In some examples, the administered IL-24 polypeptide suppresses production of effector cytokines by Th17 cells. A pharmaceutical composition is further provided here that includes an IL-24 polypeptide or nucleic acid encoding the polypeptide. In some examples, the IL-24 polypeptide is a variant of IL-24 or an Fc fusion protein that includes IL-24. The pharmaceutical composition can be used in any of the methods provided herein to treat ocular surface inflammation and/or uveitis.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 24, 2019
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rachel R. Caspi, Wai Po Chong, Reiko Yamane, Mary Mattapallil
  • Patent number: 10206999
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 19, 2019
    Assignees: Mosaic Biomedicals, S.L., Fundació Privada Institut d'Investigació Oncológica de Vall Hebron, Fundació Privada Institució Catalana de Recerca | Estudis Avançats
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira
  • Patent number: 8133730
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: March 13, 2012
    Assignee: ES Cell International PTE Ltd
    Inventor: Benjamin Eithan Reubinoff
  • Patent number: 8003104
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 23, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
  • Patent number: 7960145
    Abstract: The compositions and methods of the present invention comprise the efficient and effective presentation of antigens to the appropriate components of the immune system resulting in the production of species-specific antibodies in vitro. In general, these compositions comprise one or more antigenic components together with a colloidal metal, optionally combined with derivatized PEG (polyethylene glycol) or other agents. The invention also comprises novel cytokine cocktails for generating desired antibodies.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: June 14, 2011
    Assignee: CytImmune Sciences, Inc.
    Inventors: Giulio F. Paciotti, Ramadevi Raghunandan, Marja S. Huhta, Lawrence Tamarkin